Inhibition of USP36

Abstract

The present disclosure relates to compounds of Formulas (I)-(VI), which are useful as modulators of USP36. The compounds are further useful for inhibiting USP36 and treating diseases or disorders associated with USP36 inhibition. For example, the disclosure relates to compounds and compositions for inhibiting USP36, methods for treating diseases associated with USP36 inhibition (e.g., certain forms of cancer), and methods for synthesizing these compounds.

Description

[Technical field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Application No. 62 / 840,737, filed April 30, 2019, which is incorporated by reference in its entirety.

[0002] (Technical field) The present disclosure relates to compounds useful for the inhibition of ubiquitin-specific peptidase 36 (USP36) and methods for their preparation. Inhibitors of USP36 are useful in the treatment of several forms of cancer. [Background technology]

[0003] Aggressive cancers include subtypes of pancreatic, colon, lung, brain, ovarian, and prostate cancers, and are primarily characterized by rapid tumor formation, proliferation, and invasion. These cancers often pose a major challenge for effective treatment, particularly as they are prone to develop resistance, leading to exhaustion of treatment options in a relatively short time and generally resulting in poor prognosis. Aggressive cancers represent a high unmet medical need, and opportunities await for the development of therapies that can selectively target rapidly proliferating cancer cells while maintaining good therapeutic margins.

[0004] During cell proliferation, significant energy expenditures are driven by activities, especially in the nucleolus. These activities include ribosomal RNA (rRNA) transcription and assembly, ribosome biogenesis, cell cycle progression, DNA replication and repair, stress signaling, and cell survival. High cell proliferation rates place the nuclear vesicle under stress, and upregulation of ribosome biogenesis and associated increased metabolic resources are essential to maintain nuclear vesicle integrity. Loss of integrity may compromise the cell's replication process and promote cell death. This relationship between ribosome biogenesis, nucleolar integrity, and cell survival suggests that chemotherapy can be exploited as a mechanism to specifically affect cells with the highest nucleolar stress. Almost all types of cancer cells show evidence of nucleolar stress, such as increased nucleolar size and / or number, and nucleolar size can sometimes be a prognostic indicator of clinical outcome. This is consistent with the finding that high proliferation rates, a hallmark of aggressive cancers, are associated with high signs of nucleolar stress. Moreover, the differences in proliferation rates are also reflected in the large differences in ribosome biogenesis across cancer types. High cell proliferation rates are associated with high levels of ribosome biogenesis hyperactivation. As aggressive cancers are characterized by their rapid division, they are generally in a relatively high state of nucleolar stress, which greatly increases their metabolic demands and makes them particularly vulnerable to perturbations in ribosome production. Thus, aggressive cancers are suitable targets for therapeutic inhibition of ribosome biogenesis.

[0005] Moreover, this pathway can confer selective cytotoxicity to cancer cells while reducing the risk of widespread genotoxicity commonly seen with many other cancer treatments. Inhibition of USP36 can affect ribosome biogenesis and nucleolar integrity. USP36 is a deubiquitinase (DUB) known to be overexpressed in many cancers, including some breast, lung, and ovarian cancers. USP36 supports ribosome biogenesis and nucleolar integrity by deubiquitinating numerous nucleolar proteins (e.g., c-MYC, DHX33, and RNA Pol 1) and stabilizing them against ubiquitination-mediated proteasomal degradation. Summary of the Invention [Problem to be solved by the invention]

[0006] Since tight control of MYC levels is known to be essential for normal cell growth and proliferation, the DUB activity of USP36 against nucleolar MYC may be an important factor for therapeutic efficacy. MYC controls the expression of almost all actively transcribed genes in the human genome and orchestrates many cellular processes. MYC plays a direct role in ribosome biogenesis, RNA transcription, and protein synthesis and is highly localized in the nucleolus. In particular, pathological activation or overexpression of MYC contributes to the development of malignant tumors. Many enzymes, including USP36, are involved in the control of MYC stability and activity, which depends on the ubiquitination state. Knockdown of USP36 significantly reduces MYC levels, and this change is associated with inhibition of cell proliferation. This is consistent with the well-known view that ribosome biogenesis via high MYC activity is essential for cell growth and tumorigenesis. Inhibiting USP36 and reducing ribosome production may counteract MYC-mediated increased nucleolar activation and deplete cellular resources required for sustained proliferation, and USP36 is a MYC target gene, suggesting a positive feedback control loop. [Means for solving the problem]

[0007] Compounds of formula (I) [ka] and its pharma- ceutically acceptable salts, hydrates, solvates, isomers, and tautomers are disclosed; R1, (C1-C4)alkyl optionally substituted with 1 to 3 R2; one R3 optionally substituted (C3-C6)cycloalkyl; aryl optionally substituted with 1 to 2 R4; heteroaryl substituted with one R5; bicyclic heteroaryl optionally substituted with one (C1-C4) alkyl; partially saturated bicyclyl optionally substituted with one halogen, and [ka] Selected from; Each R2 is independently (C1-C4) alkyl, (C3-C6)cycloalkyl, (C6-C 12 ) spirocycloalkyl, aryl optionally substituted with one halogen or -OR6; and 3- to 6-membered heterocyclyl; R3 is (C1-C4) alkyl; each R4 is independently selected from (C1-C4)alkyl optionally substituted with halogen, -OR6, halogen, and 3- to 6-membered heterocyclyl; R5 is aryl substituted with one halogen; R6 is selected from aryl and (C1-C4) alkyl optionally substituted with halogen; L is -NHC(O)-; x is 0 or 1; Ar1 is heteroaryl or bicyclic heteroaryl, optionally substituted with one (C1-C4) alkyl; Ar2 is aryl or heteroaryl optionally substituted with 1-2 R7; each R7 is independently selected from aryl, halogen, trifluoromethyl, and -NHS(O)2R8; R8 is aryl optionally substituted with one R9; R9 is halogen or aryl; however, (i) when Ar2 has no or one substituent, Ar1 is not thiazolyl; and (ii) the compound [ka] Not 2-((4-fluorophenyl)sulfonamido)-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide.

[0008] In another aspect, a method for treating, preventing, inhibiting, or eliminating a disease or disorder associated with the activity of USP36 in a patient is disclosed, said method comprising administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutical composition thereof to a patient in need thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present disclosure relates to compounds that can modulate the activity of ubiquitin-specific peptidase 36 (USP36). The present disclosure features a method of treating, preventing, or ameliorating a disease or disorder in which USP36 plays a role by administering a therapeutically effective amount of a compound of any one of formulas (I)-(VI) or a pharma- ceutically acceptable salt thereof to a patient in need thereof. The method of the present disclosure can be used to treat a variety of diseases and disorders that depend on USP36 by inhibiting the activity of USP36. Inhibition of USP36 provides a new approach to the treatment of diseases, including, but not limited to, certain forms of cancer.

[0010] definition The articles "a" and "an" are used in this disclosure to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0011] The term "and / or" is used in this disclosure to mean either "and" or "or," unless otherwise indicated.

[0012] The term "optionally substituted" is understood to mean that a particular chemical moiety may (but need not) be attached to other substituents. Unless otherwise defined, an optional substituent is attached to a chemical moiety in any positional and / or stereochemistry that is chemically possible (if applicable). For example, an optionally substituted alkyl group may be a fully saturated alkyl chain (e.g., pure hydrocarbon). Alternatively, the same optionally substituted alkyl group may have a substituent in place of one or more hydrogen atoms. For example, an alkyl group may be attached to any of the recited substituents at any point along the chain. Thus, the term "optionally substituted" means that a particular chemical moiety has the potential to include other functional groups, but does not necessarily have additional functional groups. Also, as used herein, "optionally substituted" refers to substituted or unsubstituted, the meaning of which is described below.

[0013] As used herein, the term "substituted" means that the specified group or moiety bears one or more of the recited substituents, which may be attached to the specified group or moiety at a single position. Unless otherwise defined, a substituent may be attached to the chemical moiety in any regiochemistry and / or stereochemistry that is chemically possible (if applicable).

[0014] As used herein, the term "unsubstituted" means that the specified group bears no substituents.

[0015] The term "aryl" as used herein refers to a monocyclic aromatic hydrocarbon group containing one aromatic ring having a total of 5 to 14 ring atoms, such as, for example, phenyl. Unless otherwise defined, an "aryl" group is unsubstituted.

[0016] The term "heteroaryl" as used herein refers to a monocyclic aromatic radical having 5 to 14 ring atoms containing one or more ring heteroatoms selected from the group consisting of N, O, and S, with the remaining ring atoms being C. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridinyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, thiophen-2-yl, isothiazolyl, thiazolyl, thiadiazolyl, triazolyl, triazinyl. Unless otherwise defined, a "heteroaryl" group is unsubstituted.

[0017] The term "bicyclic heteroaryl" as used herein means a bicyclyl aromatic radical containing one or more ring heteroatoms selected from the group consisting of N, O, and S, with the remaining ring atoms being C.Examples include, but are not limited to, indolyl, quinolyl, benzopyranyl, indazolyl, benzimidazolyl, thieno[3,2-b]thiophene, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinyl, Dolinolyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl Lysinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a ]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, and 6,7-dihydro-4H-thieno[3.2-c]pyran.Unless otherwise defined, a "bicyclic heteroaryl" group is unsubstituted.

[0018] The term "halogen" or "halo" as used herein refers to fluorine (i.e., "F" or "fluoro"), chlorine (i.e., "Cl" or "chloro"), bromine (i.e., "Br" or "bromo"), or iodine (i.e., "i" or "iodo").

[0019] The term "(C1-C4) alkyl" as used herein refers to a straight or branched chain saturated hydrocarbon having 1 to 4 carbon atoms. Examples of (C1-C4) alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, and tert-butyl. "C1 alkyl" refers to an alkyl chain having one carbon atom, e.g., methyl. "C2 alkyl" refers to an alkyl chain having two carbon atoms, e.g., ethyl. "C3 alkyl" refers to an alkyl chain having three carbon atoms, e.g., propyl or isopropyl. "C4 alkyl" refers to an alkyl chain having four carbon atoms, e.g., butyl, isobutyl, sec-butyl, or tert-butyl. Unless otherwise defined, "(C1-C4) alkyl" groups are unsubstituted.

[0020] The term "(C3-C6)cycloalkyl" as used herein refers to a monocyclic saturated ring having 3 to 6 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. "C3 cycloalkyl" refers to a cycloalkyl having 3 carbon atoms, e.g., cyclopropyl. "C4 cycloalkyl" refers to a cycloalkyl having 4 carbon atoms, e.g., cyclobutyl. "C5 cycloalkyl" refers to a cycloalkyl having 5 carbon atoms, e.g., cyclopentyl. "C6 cycloalkyl" refers to a cycloalkyl having 6 carbon atoms, e.g., cyclohexyl. Unless otherwise defined, a "(C3-C6)cycloalkyl" group is unsubstituted.

[0021] The term "3-6 membered heterocyclyl" as used herein refers to a monocyclic ring having a total of 3-6 carbons and heteroatoms selected from oxygen, nitrogen, or sulfur, and the ring is either saturated or partially unsaturated. Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, and oxazolidinonyl. Unless otherwise defined, the "3-6 membered heterocyclyl" group is unsubstituted.

[0022] The term "partially saturated bicyclyl" as used herein refers to a bicyclic ring moiety consisting of 6-12 C atoms, in which an unsaturated or partially saturated ring is fused to a fully unsaturated ring. Examples of partially saturated bicyclyl moieties include, but are not limited to, indanyl and tetrahydronaphthalenyl. Unless otherwise defined, a "partially saturated bicyclyl" group is unsubstituted.

[0023] As used herein, "(C6-C 12The term "spirocycloalkyl" refers to a bicyclic ring system having 6-12 carbon atoms, with multiple rings bonded to each other through one atom. The multiple rings may be of different sizes or the same nature. Examples include, but are not limited to, spirohexane, spiroheptane, spirooctane, spirononane, spirodecane, spiroundecane, and spirododecane. "C6 spirocycloalkyl" refers to a spirocycloalkyl having 6 carbon atoms, e.g., spirohexane. "C7 spirocycloalkyl" refers to a spirocycloalkyl having 7 carbon atoms, e.g., spiroheptane. "C8 spirocycloalkyl" refers to a spirocycloalkyl having 8 carbon atoms, e.g., spirooctane. "C9 spirocycloalkyl" refers to a spirocycloalkyl having 9 carbon atoms, e.g., spirononane. "C 10 "Spirocycloalkyl" refers to a spirocycloalkyl having 10 carbon atoms, e.g., spirodecane. 11 "Spirocycloalkyl" refers to a spirocycloalkyl having 11 carbon atoms, e.g., spiroundecane. 12 "Spirocycloalkyl" refers to a spirocycloalkyl having 12 carbon atoms, e.g., spirododecane. Unless otherwise defined, "(C6-C 12 )spirocycloalkyl" groups are unsubstituted.

[0024] The term "isomer" as used herein refers to compounds that have the same composition and molecular weight but different physical and / or chemical properties. The structural difference may be in constitution (e.g., geometric isomers) or in ability to rotate the plane of polarized light (stereoisomers). With respect to stereoisomers, the compounds of formula (I) may have one or more asymmetric carbon atoms and may exist as racemates, racemic mixtures, or as individual enantiomers or diastereomers.

[0025] As used herein, the term "pharmaceutical composition" refers to a composition in which the individual components or ingredients are themselves pharma- ceutical acceptable, e.g., when oral administration is anticipated, it is orally acceptable; when topical administration is anticipated, it is topically acceptable; and when intravenous administration is anticipated, it is acceptable for intravenous administration.

[0026] The term "solvate" refers to a complex of variable stoichiometry formed by a solute and a solvent. For the purposes of this disclosure, such a solvent may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates in which water is the solvent molecule are generally referred to as hydrates. Hydrates include compositions that contain stoichiometric amounts of water as well as compositions that contain variable amounts of water.

[0027] "Pharmaceutically acceptable salts" are well known in the art. For example, SM Berge et al. describe pharma- ceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Representative pharma-ceutically acceptable salts include, for example, water-soluble salts and water-insoluble salts, such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium salt, calcium edetate, camsylate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate. Salt, estolate, esylate, fumarate, fiunarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, magnesium salt, malate, maleate, mandelate, mesylate, methyl bromide, nitrate Salts include methyl, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium, 2-hydroxy-3-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, embonate, pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, theoclate, tosylate, triethiodide, and valerate. Compounds of formula (I)-(VI) can form salts which are also within the scope of the present disclosure. Reference herein to a compound of formula I is understood to include a reference to salts thereof, unless otherwise indicated.

[0028] New USP36 inhibitors are provided. Unless otherwise specified, a "USP36 inhibitor compound" as used herein refers to a compound that has a detectable IC when tested according to the USP36 inhibition biochemical assay in Example 9 below. 50 It refers to compounds having a value of 10 micromolar or less. The USP36 inhibitor compounds of the present disclosure can be administered at therapeutically effective levels.

[0029] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate such as a monkey, chimpanzee, baboon, or rhesus monkey.

[0030] As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic agent sufficient to ameliorate one or more symptoms of a disorder, or to prevent the progression of a disorder, or to cause regression of a disorder.

[0031] The term "carrier" as used herein encompasses carriers, excipients, and diluents and means a material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that is involved in carrying or transporting a therapeutic agent from one organ or body part of a subject to another organ or body part.

[0032] The term "treatment" with respect to a subject refers to ameliorating at least one symptom of the subject's disorder. Treatment includes curing, amelioration, or at least partial amelioration of the disorder.

[0033] The term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms "disease," "condition," or "illness," unless otherwise indicated.

[0034] The terms "administer", "administering", or "administration" as used in this disclosure refer to either directly administering to a subject a compound of the disclosure, a pharma- ceutically acceptable salt of a compound of the disclosure, or a composition comprising a compound of the disclosure, or administering to a subject a pharma- ceutically acceptable salt of the compound or a composition that is capable of forming an equivalent amount of the active compound in the subject's body.

[0035] Compounds of the Disclosure The present disclosure relates to compounds that can modulate USP36 and are useful for treating diseases and disorders associated with the modulation of USP36, or pharma- ceutically acceptable salts, hydrates, solvates, tautomers, and isomers thereof. The present disclosure further relates to compounds that are useful for inhibiting USP36, or pharma-ceutically acceptable salts, hydrates, solvates, tautomers, and isomers thereof.

[0036] Compounds of the Disclosure Unless otherwise indicated herein, all isomeric forms of a particular chemical compound, including mixtures thereof, are provided by the present disclosure. All tautomeric forms are also intended to be included.

[0037] The compounds of formulae (I)-(VI), unless otherwise indicated, contain one or more stereocenters and therefore may exist in different stereoisomeric forms. Unless otherwise indicated, all stereoisomeric forms of the compounds of formulae (I)-(VI), such as enantiomeric (even when no asymmetric carbon is present), rotameric, atropisomeric, and diastereomeric forms, as well as mixtures thereof, including racemic mixtures, are intended to form part of the present disclosure. Furthermore, the present disclosure encompasses all geometric and positional isomers. For example, if a compound of any one of formulae (I)-(VI) contains a double bond or a fused ring, both the cis and trans forms, as well as mixtures thereof, are encompassed within the scope of the present disclosure. Each compound disclosed herein includes all enantiomers that conform to the general structure of the compound. The compounds may be in racemic or enantiomerically pure form, or in any other stereochemical form. Analytical results may reflect data collected for racemic forms, enantiomerically pure forms, or any other stereochemical forms. Individual stereoisomers of the compounds of the present disclosure may be, for example, substantially free of other isomers, e.g., as racemates, or mixed with all or selected other stereoisomers. In some embodiments of the present disclosure, the compounds of formulas (I)-(VI) are enantiomers. In some embodiments, the compounds are (S)-enantiomers. In other embodiments, the compounds are (R)-enantiomers. In some embodiments, the compounds of formulas (I)-(VI) may be (+) or (-) enantiomers.

[0038] Diastereomeric mixtures can be separated into individual diastereomers based on their physical chemical differences by methods known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture to a diastereomeric mixture by reaction with a suitable optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers to the corresponding pure enantiomers (e.g., by hydrolysis). Some of the compounds of formulas (I)-(VI) may also be atropisomers (e.g., substituted biaryls) and are considered part of this disclosure. Enantiomers can also be separated by use of a chiral HPLC column.

[0039] In addition, unless otherwise stated, the present disclosure encompasses all geometric and positional isomers (e.g., 4-pyridyl, 3-pyridyl, etc.). For example, when a compound of the present disclosure contains a double bond or a fused ring, both cis and trans forms and mixtures thereof are encompassed within the scope of the present disclosure. When a compound has a double bond, the substituent may be in either E or Z configuration, unless otherwise stated. When a compound has a disubstituted cycloalkyl, the cycloalkyl substituent may be in either cis or trans configuration, unless otherwise stated.

[0040] The compounds of the present disclosure, as well as their pharma- ceutically acceptable salts and stereoisomers, may exist in tautomeric form (e.g., as amide or imino ether).Furthermore, all keto-enol and imine-enamine forms of the compounds are also included in the present disclosure.All such tautomeric forms are considered herein as part of the present disclosure.

[0041] Use of terms like "salts" is intended to apply equally to the enantiomers, stereoisomers, rotamers, tautomers, positional isomers, and racemic salts of the compounds of the present invention.

[0042] When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of the compound, neat or in a suitable inert solvent, with a sufficient amount of the desired base. Salts derived from pharma- ceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese, potassium, sodium, zinc, and the like. Salts derived from pharma- ceutically acceptable organic bases include salts of primary, secondary, tertiary, and quaternary amines such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like, substituted amines, cyclic amines, and naturally occurring amines.

[0043] In the case where the compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Acids suitable for preparing pharmaceutically acceptable acid addition salts include acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glucoronic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalenesulfonic acid, nicotinic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, and the like.

[0044] The compounds of formulas (I) to (VI) may form acid addition salts or base addition salts, which may be pharma-ceutically acceptable salts.

[0045] Compounds of formula (I) [ka] and its pharma- ceutically acceptable salts, hydrates, solvates, isomers, and tautomers are disclosed; R1, (C1-C4)alkyl optionally substituted with 1 to 3 R2; one R3 optionally substituted (C3-C6)cycloalkyl; aryl optionally substituted with 1 to 2 R4; heteroaryl substituted with one R5; bicyclic heteroaryl optionally substituted with one (C1-C4) alkyl; partially saturated bicyclyl optionally substituted with one halogen, and [ka] Selected from; Each R2 is independently (C1-C4) alkyl, (C3-C6)cycloalkyl, (C6-C 12 ) spirocycloalkyl, aryl optionally substituted with one halogen or -OR6; and selected from 3- to 6-membered heterocyclyl; R3 is (C1-C4) alkyl; each R4 is independently selected from (C1-C4)alkyl optionally substituted with halogen, -OR6, halogen, and 3- to 6-membered heterocyclyl; R5 is aryl substituted with one halogen; R6 is selected from aryl and (C1-C4) alkyl optionally substituted with halogen; L is -NHC(O)-; x is 0 or 1; Ar1 is heteroaryl or bicyclic heteroaryl, optionally substituted with one (C1-C4) alkyl; Ar2 is aryl or heteroaryl optionally substituted with 1-2 R7; each R7 is independently selected from aryl, halogen, trifluoromethyl, and -NHS(O)2R8; R8 is aryl optionally substituted with one R9; R9 is halogen or aryl; however, (i) when Ar2 has no or one substituent, Ar1 is not thiazolyl; and (ii) the compound [ka] Not 2-((4-fluorophenyl)sulfonamido)-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide.

[0046] In some embodiments, the compound of formula (I) is further represented by the formula (Ia): [ka] and pharma- ceutically acceptable salts, hydrates, solvates, isomers, and tautomers thereof; R1, (C1-C4)alkyl optionally substituted with 1 to 3 R2; (C3-C6)cycloalkyl optionally substituted with one R3 or fused with an aryl to form a bicyclyl optionally substituted with one halogen; aryl optionally substituted with 1 to 2 R4; heteroaryl substituted with one R5; bicyclic heteroaryl optionally substituted with one (C1-C4) alkyl; Partially saturated bicyclyl, and [ka] Selected from; R2, (C1-C4) alkyl, (C3-C6)cycloalkyl, optionally fused with a (C3-C6)cycloalkyl to form a spiro ring; aryl, optionally substituted with one halogen; and selected from 3- to 6-membered heterocyclyl; R3 is (C1-C4) alkyl; R4 is selected from (C1-C4)alkyl optionally substituted with halogen, -OR6, halogen, and 3- to 6-membered heterocyclyl; R5 is aryl substituted with one halogen; R6 is selected from aryl and (C1-C4) alkyl optionally substituted with halogen; L is -NHC(O)-; x is 0 or 1; Ar1 is heteroaryl or bicyclic heteroaryl, optionally substituted with one (C1-C4) alkyl; Ar2 is aryl or heteroaryl optionally substituted with 1-2 R7; R7 is selected from aryl, halogen, trifluoromethyl, and -NHS(O)2R8; R8 is aryl optionally substituted with one R9; R9 is halogen or aryl.

[0047] In some embodiments, R1 is selected from the group consisting of (C1-C4) alkyl optionally substituted with 1-3 R2, (C3-C6) cycloalkyl optionally substituted with 1 R3, aryl optionally substituted with 1-2 R4, heteroaryl substituted with 1 R5, bicyclic heteroaryl substituted with 1 (C1-C4) alkyl, and [ka] Selected from

[0048] In some embodiments, R1 is a (C1-C4) alkyl optionally substituted with 1-3 R2. In some embodiments, R1 is a C1 alkyl substituted with 1 R2. In some embodiments, R1 is a C1 alkyl substituted with 2 R2. In some embodiments, R6 is a C1 alkyl substituted with 3 R2. In some embodiments, R1 is an unsubstituted C1 alkyl. In some embodiments, R1 is a C2 alkyl substituted with 1 R2. In some embodiments, R6 is a C2 alkyl substituted with 2 R2. In some embodiments, R1 is a C2 alkyl substituted with 3 R2. In some embodiments, R1 is an unsubstituted C2 alkyl. In some embodiments, R1 is a methyl substituted with 1 R2. In some embodiments, R1 is a methyl substituted with 2 R2. In some embodiments, R1 is a methyl substituted with 3 R2. In some embodiments, R1 is an unsubstituted methyl. In some embodiments, R1 is ethyl substituted with one R3. In some embodiments, R1 is ethyl substituted with two R2. In some embodiments, R3 is ethyl substituted with three R2. In some embodiments, R1 is unsubstituted ethyl.

[0049] In some embodiments, R1 is (C3-C6)cycloalkyl, optionally substituted with one R3. In some embodiments, R1 is C6 cycloalkyl, optionally substituted with one R3. In some embodiments, R1 is C6 cycloalkyl, substituted with one R3. In some embodiments, R1 is cyclohexyl, optionally substituted with one R3. In some embodiments, R1 is cyclohexyl, substituted with one R3.

[0050] In some embodiments, R1 is aryl, optionally substituted with one to two R4. In some embodiments, R1 is aryl substituted with one R4. In some embodiments, R1 is aryl substituted with two R4. In some embodiments, R1 is unsubstituted aryl. In some embodiments, R1 is phenyl substituted with one R4. In some embodiments, R1 is phenyl substituted with two R4. In some embodiments, R1 is unsubstituted phenyl. In some embodiments, R1 is indanyl substituted with one R4. In some embodiments, R1 is unsubstituted indanyl. In some embodiments, R1 is unsubstituted tetrahydronaphthenyl.

[0051] In some embodiments, R1 is heteroaryl substituted with 1 R5. In some embodiments, R1 is pyrazolyl substituted with 1 R5.

[0052] In some embodiments, R1 is a bicyclic heteroaryl substituted with one (C1-C4) alkyl. In some embodiments, R1 is a bicyclic heteroaryl substituted with one C3 alkyl. In some embodiments, R1 is a bicyclic heteroaryl substituted with one isopropyl. In some embodiments, R1 is an indazolyl substituted with one (C1-C4) alkyl. In some embodiments, R1 is an indazolyl substituted with one C3 alkyl. In some embodiments, R1 is an indazolyl substituted with one isopropyl.

[0053] In some embodiments, R1 is [ka] It is.

[0054] In some embodiments, R2 is (C1-C4) alkyl, (C3-C6) cycloalkyl, (C6-C 12) spirocycloalkyl, aryl optionally substituted with one halogen or -OR6, and 3- to 6-membered heterocyclyl.

[0055] In some embodiments, R2 is (C1-C4) alkyl. In some embodiments, R2 is C1 alkyl. In some embodiments, R2 is methyl.

[0056] In some embodiments, R2 is (C3-C6)cycloalkyl.

[0057] In some embodiments, R2 is (C6-C 12 ) spirocycloalkyl. In some embodiments, R2 is C spirocycloalkyl. In some embodiments, R2 is spirooctane. In some embodiments, R2 is spiro[5.2]octane.

[0058] In some embodiments, R2 is aryl, optionally substituted with one halogen or -OR6. In some embodiments, R2 is unsubstituted aryl. In some embodiments, R2 is unsubstituted phenyl. In some embodiments, R2 is aryl substituted with one halogen. In some embodiments, R2 is aryl substituted with one Cl. In some embodiments, R2 is phenyl substituted with one halogen. In some embodiments, R2 is phenyl substituted with one Cl.

[0059] In some embodiments, R2 is aryl substituted with one -OR6. In some embodiments, R2 is phenyl substituted with one -OR6.

[0060] In some embodiments, R2 is 3-6 membered heterocyclyl. In some embodiments, R2 is 5 membered heterocyclyl. In some embodiments, R2 is pyrrolidinyl.

[0061] In some embodiments, R2 is selected from the group consisting of methyl, cyclopropyl fused to cyclohexyl, pyrrolidinyl, and phenyl optionally substituted with one -Cl.

[0062] In some embodiments, R3 is (C1-C4) alkyl. In some embodiments, R3 is C4 alkyl. In some embodiments, R3 is tert-butyl. In some embodiments, R4 is selected from (C1-C4)alkyl optionally substituted with halogen, -OR6, halogen, and 3- to 6-membered heterocyclyl.

[0063] In some embodiments, R4 is a (C1-C4) alkyl optionally substituted with halogen. In some embodiments, R4 is a C1 alkyl optionally substituted with halogen. In some embodiments, R4 is an unsubstituted C1 alkyl. In some embodiments, R4 is a C1 alkyl substituted with halogen. In some embodiments, R4 is a C1 alkyl substituted with one halogen. In some embodiments, R4 is a C1 alkyl substituted with two halogens. In some embodiments, R4 is a C1 alkyl substituted with three halogens. In some embodiments, R2 is a C1 alkyl substituted with two F. In some embodiments, R2 is a C1 alkyl substituted with three F. In some embodiments, R2 is a methyl optionally substituted with halogen. In some embodiments, R4 is an unsubstituted methyl. In some embodiments, R4 is a methyl substituted with halogen. In some embodiments, R4 is a methyl substituted with one halogen. In some embodiments, R4 is a methyl substituted with two halogens. In some embodiments, R4 is methyl substituted with three halogens. In some embodiments, R4 is methyl substituted with two Fs. In some embodiments, R2 is difluoromethyl. In some embodiments, R4 is C1 alkyl substituted with three Fs. In some embodiments, R4 is trifluoromethyl. In some embodiments, R4 is C3 alkyl optionally substituted with halogens. In some embodiments, R4 is unsubstituted C3 alkyl. In some embodiments, R4 is isopropyl optionally substituted with halogens. In some embodiments, R4 is unsubstituted isopropyl.

[0064] In some embodiments, R4 is -OR6.

[0065] In some embodiments, R4 is a halogen. In some embodiments, R4 is a halogen selected from F, Cl, Br, and I. In some embodiments, R4 is a halogen selected from Cl, Br, and I. In some embodiments, R4 is a halogen selected from F, Cl, and Br. In some embodiments, R4 is a halogen selected from F, Cl, and I. In some embodiments, R4 is F. In some embodiments, R4 is Cl. In some embodiments, R4 is Br. In some embodiments, R4 is I.

[0066] In some embodiments, R4 is 3-6 membered heterocyclyl. In some embodiments, R4 is 5 membered heterocyclyl. In some embodiments, R4 is pyrrolidinyl.

[0067] In some embodiments, R4 is selected from the group consisting of methyl, isopropyl, trifluoromethyl, -Cl, and pyrrolidinyl.

[0068] In some embodiments, R5 is aryl substituted with one halogen. In some embodiments, R5 is aryl substituted with one halogen selected from F, Cl, Br, and I. In some embodiments, R5 is aryl substituted with one F. In some embodiments, R5 is aryl substituted with one Cl. In some embodiments, R5 is aryl substituted with one Br. In some embodiments, R5 is aryl substituted with one I. In some embodiments, R5 is phenyl substituted with one halogen. In some embodiments, R5 is phenyl substituted with one halogen selected from F, Cl, Br, and I. In some embodiments, R5 is phenyl substituted with one F. In some embodiments, R5 is phenyl substituted with one Cl. In some embodiments, R5 is phenyl substituted with one Br. In some embodiments, R5 is phenyl substituted with one I.

[0069] In some embodiments, R6 is selected from aryl and (C1-C4) alkyl optionally substituted with halogen.

[0070] In some embodiments, R6 is aryl. In some embodiments, R6 is phenyl.

[0071] In some embodiments, R6 is (C1-C4) alkyl optionally substituted with halogen. In some embodiments, R6 is C1 alkyl optionally substituted with halogen. In some embodiments, R6 is unsubstituted C1 alkyl. In some embodiments, R 46is a C1 alkyl substituted with a halogen. In some embodiments, R6 is a C1 alkyl substituted with one halogen. In some embodiments, R6 is a C1 alkyl substituted with two halogens. In some embodiments, R6 is a C1 alkyl substituted with three halogens. In some embodiments, R6 is a C1 alkyl substituted with two F. In some embodiments, R6 is a C1 alkyl substituted with three F. In some embodiments, R6 is methyl optionally substituted with a halogen. In some embodiments, R6 is unsubstituted methyl. In some embodiments, R6 is methyl substituted with a halogen. In some embodiments, R6 is methyl substituted with one halogen. In some embodiments, R6 is methyl substituted with two halogens. In some embodiments, R6 is methyl substituted with three halogens. In some embodiments, R6 is methyl substituted with two F. In some embodiments, R6 is difluoromethyl. In some embodiments, R6 is a C1 alkyl substituted with three F. In some embodiments, R6 is trifluoromethyl. In some embodiments, R6 is C3 alkyl optionally substituted with halogen. In some embodiments, R6 is unsubstituted C3 alkyl. In some embodiments, R6 is isopropyl optionally substituted with halogen. In some embodiments, R6 is unsubstituted isopropyl.

[0072] In some embodiments, R6 is selected from the group consisting of phenyl, isopropyl, difluoromethyl, and trifluoromethyl.

[0073] In some embodiments, x is 0. In some embodiments, x is 1.

[0074] In some embodiments, Ar1 is heteroaryl or bicyclic heteroaryl, which may be optionally substituted with one (C1-C4) alkyl. In some embodiments, Ar1 is heteroaryl, which may be optionally substituted with one (C1-C4) alkyl. In some embodiments, Ar1 is heteroaryl substituted with one (C1-C4) alkyl. In some embodiments, Ar1 is isothiazolyl substituted with one C1 alkyl. In some embodiments, Ar1 is isothiazolyl substituted with one methyl. In some embodiments, Ar1 is unsubstituted heteroaryl. In some embodiments, Ar1 is unsubstituted 1,2,3-thiadiazolyl. In some embodiments, Ar1 is 1,2,4-thiadiazolyl. In some embodiments, Ar1 is unsubstituted thiazolyl. In some embodiments, Ar1 is bicyclic heteroaryl, which may be optionally substituted with one (C1-C4) alkyl. In some embodiments, Ar1 is bicyclic heteroaryl substituted with one (C1-C4) alkyl. In some embodiments, Ar1 is an unsubstituted bicyclic heteroaryl. In some embodiments, Ar1 is an unsubstituted 6,7-dihydro-4H-thieno[3.2-c]pyran.

[0075] In some embodiments, Ar2 is aryl or heteroaryl, optionally substituted with 1-2 R7. In some embodiments, Ar2 is unsubstituted aryl. In some embodiments, Ar2 is aryl substituted with one R7. In some embodiments, Ar2 is phenyl substituted with one R7. In some embodiments, Ar2 is aryl substituted with two R7. In some embodiments, Ar2 is phenyl substituted with two R7. In some embodiments, Ar2 is unsubstituted heteroaryl. In some embodiments, Ar2 is heteroaryl substituted with one R7. In some embodiments, Ar2 is pyridinyl substituted with one R7. In some embodiments, Ar2 is 1,2,3-thiazolyl substituted with one R7. In some embodiments, Ar2 is heteroaryl substituted with two R7.

[0076] In some embodiments, R7 is selected from aryl, halogen, trifluoromethyl, and -NHS(O)2R8. In some embodiments, R7 is aryl. In some embodiments, R7 is phenyl. In some embodiments, R7 is halogen. In some embodiments, R7 is halogen selected from F, Cl, Br, and I. In some embodiments, R7 is F. In some embodiments, R7 is Cl. In some embodiments, R7 is Br. In some embodiments, R7 is I. In some embodiments, R7 is trifluoromethyl. In some embodiments, R7 is -NHSO(O)2R8.

[0077] In some embodiments, R8 is aryl, optionally substituted with one R9. In some embodiments, R8 is unsubstituted aryl. In some embodiments, R8 is aryl, substituted with one R9. In some embodiments, R8 is phenyl, optionally substituted with one R9. In some embodiments, R8 is unsubstituted phenyl. In some embodiments, R8 is phenyl, substituted with one R9.

[0078] In some embodiments, R9 is halogen or aryl. In some embodiments, R9 is halogen. In some embodiments, R9 is halogen selected from F, Cl, Br, and I. In some embodiments, R9 is F. In some embodiments, R9 is Cl. In some embodiments, R9 is Br. In some embodiments, R9 is I. In some embodiments, R9 is aryl. In some embodiments, R9 is phenyl.

[0079] In some embodiments, the compound of formula (I) is selected from the group consisting of the compounds listed in Table A.

[0080] In some embodiments, the present disclosure provides a compound of formula (I) further provided by formula (II): [ka] and its pharma- ceutically acceptable salts, hydrates, solvates, isomers, and tautomers, Y is N or CH; R 10 is hydrogen or a halogen; R 11 is halogen or (C1-C3) alkyl substituted with halogen.

[0081] In some embodiments, R 10 is hydrogen or halogen. In some embodiments, R 10 is hydrogen. In some embodiments, R10 is halogen. In some embodiments, R 10 is a halogen selected from F, Cl, Br, and I. In some embodiments, R 10 is hydrogen or Cl. In some embodiments, R 10 is Cl.

[0082] In some embodiments, R 11 is halogen or (C-C)alkyl substituted with halogen. In some embodiments, R 11 is a halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 11 is (C-C) alkyl substituted with halogen. In some embodiments, R 11 is (C-C)alkyl substituted with one halogen. In some embodiments, R 11 is (C-C) alkyl substituted with two halogens. In some embodiments, R 11 is (C-C)alkyl substituted with three halogens. In some embodiments, R 11 is C alkyl substituted with halogen. In some embodiments, R 11 is C alkyl substituted with one halogen. In some embodiments, R 11 is a C alkyl substituted with two halogens. In some embodiments, R 11 is a C alkyl substituted with three halogens. In some embodiments, R 11 is methyl substituted with halogen. In some embodiments, R 11 is methyl substituted with one halogen. In some embodiments, R 11 is methyl substituted with two halogens. In some embodiments, R 11 is methyl substituted with three halogens. In some embodiments, R 11 is Cl or trifluoromethyl. In some embodiments, R 11is Cl. In some embodiments, R 11 is trifluoromethyl.

[0083] In some embodiments, the compound of formula (II) is [ka] [ka] [ka] or a pharma- ceutically acceptable salt or isomer thereof.

[0084] In some embodiments, the present disclosure provides a compound of formula (I) further provided by formula (III): [ka] and its pharma- ceutically acceptable salts, hydrates, solvates, isomers, and tautomers, Z is N or CH; R 12 is hydrogen or (C1-C4) alkyl substituted with one or more halogen atoms; R 13 is aryl or halogen.

[0085] In some embodiments, R 12 is hydrogen or (C-C) alkyl substituted with one or more halogen atoms. In some embodiments, R 12 is (C1-C4) alkyl substituted with one or more halogen atoms. In some embodiments, R 12 is (C-C)alkyl substituted with one halogen. In some embodiments, R 12 is (C-C) alkyl substituted with two halogens. In some embodiments, R 12 is (C-C)alkyl substituted with three halogens. In some embodiments, R12 is C alkyl substituted with halogen. In some embodiments, R 12 is C alkyl substituted with one halogen. In some embodiments, R 12 is a C alkyl substituted with two halogens. In some embodiments, R 12 is a C alkyl substituted with three halogens. In some embodiments, R 12 is methyl substituted with halogen. In some embodiments, R 12 is methyl substituted with one halogen. In some embodiments, R 12 is methyl substituted with two halogens. In some embodiments, R 12 is methyl substituted with three halogens. In some embodiments, R 12 is hydrogen or trifluoromethyl. In some embodiments, R 12 is hydrogen. In some embodiments, R 12 is trifluoromethyl.

[0086] In some embodiments, R 13 is aryl or halogen. In some embodiments, R 13 is aryl. In some embodiments, R 13 is halogen. In some embodiments, R 13 is a halogen selected from F, Cl, Br, and I. In some embodiments, R 13 is phenyl or Cl. In some embodiments, R 13 is phenyl. In some embodiments, R 13 is Cl.

[0087] In some embodiments, the compound of formula (III) is [ka] or a pharma- ceutically acceptable salt thereof.

[0088] In some embodiments, the present disclosure provides a compound of formula (I) further provided by formula (IV): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate, isomer, or tautomer thereof, R 14 is aryl substituted with halogen; R 15 is aryl.

[0089] In some embodiments, R 14 is aryl substituted with halogen. In some embodiments, R 14 is aryl substituted with one halogen. In some embodiments, R 14 is aryl substituted with one halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 14 is aryl substituted with one Cl. In some embodiments, R 14 is phenyl substituted with halogen. In some embodiments, R 14 is phenyl substituted with one halogen. In some embodiments, R 14 is phenyl substituted with one halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 14 is a phenyl substituted with one Cl.

[0090] In some embodiments, R 15 is aryl. In some embodiments, R 15 is phenyl.

[0091] In some embodiments, the compound of formula (IV) is [ka] or a pharma- ceutically acceptable salt thereof.

[0092] In some embodiments, the present disclosure provides a compound of formula (I) further provided by formula (V): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate, isomer, or tautomer thereof, R 16 is a halogen; R 17 is (C1-C4) alkyl substituted with halogen; R 18 is an aryl substituted with a halogen.

[0093] In some embodiments, R 16 is halogen. In some embodiments, R 16 is a halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 16 is Cl.

[0094] In some embodiments, R 17 is (C-C) alkyl substituted with halogen. In some embodiments, R 17 is C alkyl substituted with halogen. In some embodiments, R 17 is a C alkyl substituted with three halogens. In some embodiments, R 17 is C alkyl substituted with three halogens selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 17 is C alkyl substituted with 3 F. In some embodiments, R 17 is methyl substituted with halogen. In some embodiments, R 17 is methyl substituted with three halogens. In some embodiments, R 17 is methyl substituted with three halogens selected from the group consisting of F, Cl, Br, and I. In some embodiments, R is methyl substituted with three F. In some embodiments, R 17is trifluoromethyl.

[0095] In some embodiments, R 18 is aryl substituted with halogen. In some embodiments, R 18 is aryl substituted with one halogen. In some embodiments, R 18 is aryl substituted with one halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 18 is aryl substituted with one Cl. In some embodiments, R 18 is phenyl substituted with halogen. In some embodiments, R 18 is phenyl substituted with one halogen. In some embodiments, R 18 is phenyl substituted with one halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 18 is a phenyl substituted with one Cl.

[0096] In some embodiments, the compound of formula (V) [ka] or a pharma- ceutically acceptable salt thereof.

[0097] In some embodiments, the present disclosure provides a compound of formula (I) further provided by formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate, isomer, or tautomer thereof, R 19 is a halogen; R 20 is (C1-C4) alkyl substituted with halogen; R 21 is an aryl substituted with a halogen.

[0098] In some embodiments, R 19 is halogen. In some embodiments, R 19 is a halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 19 is Cl.

[0099] In some embodiments, R 20 is (C-C) alkyl substituted with halogen. In some embodiments, R 20 is C alkyl substituted with halogen. In some embodiments, R 20 is a C alkyl substituted with three halogens. In some embodiments, R 20 is C alkyl substituted with three halogens selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 20 is C alkyl substituted with 3 F. In some embodiments, R 20 is methyl substituted with halogen. In some embodiments, R 20 is methyl substituted with three halogens. In some embodiments, R 20 is methyl substituted with three halogens selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 20 is methyl substituted with three F. In some embodiments, R 20 is trifluoromethyl.

[0100] In some embodiments, R 21 is aryl substituted with halogen. In some embodiments, R 21 is aryl substituted with one halogen. In some embodiments, R 21 is aryl substituted with one halogen selected from the group consisting of F, Cl, Br, and I. In some embodiments, R 21 is aryl substituted with one Cl. In some embodiments, R 21is phenyl substituted with halogen. In some embodiments, R 21 is phenyl substituted with one halogen. In some embodiments, R 21 is phenyl substituted with one halogen selected from F, Cl, Br, and I. In some embodiments, R 21 is a phenyl substituted with one Cl.

[0101] In some embodiments, the compound of formula (VI) is [ka] or a pharma- ceutically acceptable salt thereof. The compound of formula (I) 2-((4-fluorophenyl)sulfonamido)-N-(4-phenylthiazol-2-yl)benzamide; 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(2,5-dimethoxyphenyl)-2-thiazolyl]-benzamide; N-[4-(1,3-benzodioxol-5-yl)-2-thiazolyl]-2-[[(4-chlorophenyl)sulfonyl]amino]-benzamide; N-[4-(3,4-dimethoxyphenyl)-2-thiazolyl]-2-[[(4-fluorophenyl)sulfonyl]amino]-benzamide; N-[4-(2,4-dimethoxyphenyl)-2-thiazolyl]-2-[[(4-fluorophenyl)sulfonyl]amino]-benzamide; 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(2,4-dimethoxyphenyl)-2-thiazolyl]-benzamide; 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thiazolyl]-benzamide; N-[4-(2,5-dimethoxyphenyl)-2-thiazolyl]-2-[[(4-fluorophenyl)sulfonyl]amino]-benzamide; 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(3,4-dimethoxyphenyl)-2-thiazolyl]-benzamide; N-[4-(2,5-dimethoxyphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; N-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thiazolyl]-2-[[(4-fluorophenyl)sulfonyl]amino]-benzamide; 2-[[(4-fluorophenyl)sulfonyl]amino]-N-[4-(4-fluorophenyl)-2-thiazolyl]-benzamide; N-[4-(2,4-dimethoxyphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; 2-[[(4-fluorophenyl)sulfonyl]amino]-N-(3-phenyl-1,2,4-thiadiazol-5-yl)-benzamide; N-[4-(4-ethoxyphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; 2-[[(4-fluorophenyl)sulfonyl]amino]-N-[4-(4-methoxyphenyl)-2-thiazolyl]-benzamide; N-[4-(3,4-dimethoxyphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; N-[4-(4-methoxyphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; N-[4-(4-ethoxyphenyl)-2-thiazolyl]-2-[[(4-fluorophenyl)sulfonyl]amino]-benzamide; N-[4-(1,3-benzodioxol-5-yl)-2-thiazolyl]-2-[[(4-fluorophenyl)sulfonyl]amino]-benzamide; N-[4-(4-methoxy-3-methylphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; N-[4-(1,3-benzodioxol-5-yl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; N-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; 2-[[(4-fluorophenyl)sulfonyl]amino]-N-[4-(4-methoxy-3-methylphenyl)-2-thiazolyl]-benzamide; N-[4-(4-fluorophenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; N-[4-(4-methylphenyl)-2-thiazolyl]-2-[(phenylsulfonyl)amino]-benzamide; 2-[[(4-fluorophenyl)sulfonyl]amino]-N-[4-(4-methylphenyl)-2-thiazolyl]-benzamide; 2-[[(4-fluorophenyl)sulfonyl]amino]-N-[4-[4-(1-methylethyl)phenyl]-2-thiazolyl]-benzamide; or Not 2-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(2-naphthalenyl)-2-thiazolyl]-benzamide.

[0102] Non-limiting specific embodiments of USP36 inhibitor compounds are shown in Table A below.

[0103] Methods for Preparing the Compounds of the Disclosure The compounds of the present disclosure can be made by a variety of methods, including standard chemical techniques. Suitable synthetic routes are illustrated in the Examples below.

[0104] The compounds of the present disclosure, i.e., compounds of formulae (I)-(VI) or pharma-ceutically acceptable salts thereof, may be prepared by methods known in the art of organic synthesis, some of which are illustrated in the synthetic schemes shown in the Examples. In the schemes described below, it is fully understood that protecting groups for sensitive or reactive groups may be used as necessary, according to general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at the appropriate stage of the compound synthesis in a manner readily known by those skilled in the art. The processes selected, as well as the reaction conditions and the order in which they are carried out, are consistent with the preparation of the compounds of formulae (I)-(VI).

[0105] Those skilled in the art will recognize that stereocenters exist in the compounds of formulas (I)-(VI). Thus, the present disclosure includes both possible stereoisomers (unless otherwise indicated and / or specified in the synthesis), including racemates as well as individual enantiomers and / or diastereomers. Unless otherwise indicated, if a compound is desired to be a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by resolution of the final product or any suitable intermediate. Resolution of the final product, intermediate, or starting material may be affected by any suitable method known in the art. See, for example, EL Eliel, SH Wilen, and LN Mander "Stereochemistry of Organic Compounds" (Wiley-lnterscience, 1994).

[0106] Methods of Use of the Disclosed Compounds One embodiment of the present disclosure relates to a compound of any one of formulas (I)-(VI) for use in medicine. Another embodiment of the present disclosure relates to a method for modulating USP36, comprising administering a therapeutically effective amount of a compound of any one of formulas (I)-(VI) to a patient in need thereof. Another embodiment of the present disclosure relates to a method for inhibiting one or more of USP36, comprising administering a therapeutically effective amount of a compound of any one of formulas (I)-(VI) to a patient in need thereof. In another embodiment, the present disclosure relates to a method for inhibiting USP36, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of any one of formulas (I)-(VI) to a patient in need thereof.

[0107] USP36 inhibitor compounds are useful for the development of pharmaceutical compositions suitable for the treatment of certain forms of cancer, including, but not limited to, pancreatic cancer, colon cancer, lung cancer, brain cancer, ovarian cancer, or prostate cancer. USP36 inhibitor compounds are useful for the treatment of disease states that respond to the inhibition of USP36. The present disclosure relates to the treatment of certain forms of cancer. Inhibition of USP36 selectively induces cancer cell cycle arrest and apoptosis by reducing ribosome biogenesis and transcription, inhibiting downstream protein synthesis, and adversely affecting nucleolar morphology. Based on the relationship between USP36, MYC, and ribosome production, upregulation of nucleolar stress caused by MYC is a marker of differential levels of nucleolar stress and thus vulnerability to inhibition of ribosome biogenesis. This may provide a mechanism for identifying the types of cancer cells that are most likely to be affected by the inhibition of USP36.

[0108] The present disclosure also encompasses a pharmaceutical composition comprising an effective amount of a compound of any one of formulas (I)-(VI) of the present disclosure and a pharma- ceutically acceptable carrier.

[0109] The present disclosure also encompasses pharmaceutical compositions comprising one or more compounds as described herein or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier. In some embodiments, the pharmaceutical compositions reported herein can be provided in unit dosage form (e.g., capsules, tablets, etc.).

[0110] In some embodiments, the pharmaceutical compositions reported herein can be provided in an oral dosage form. In some embodiments, the oral dosage form of the compound of any one of Formulas (I)-(VI) can be a capsule. In some embodiments, the oral dosage form of the compound of any one of Formulas (I)-(VI) is a tablet. In some embodiments, the oral dosage form includes one or more fillers, disintegrants, lubricants, glidants, anti-adherents, and / or antistatic agents. In some embodiments, the oral dosage form is prepared by dry blending. In some embodiments, the oral dosage form is a tablet and is prepared by dry granulation.

[0111] The composition according to the present invention may be used for administration in any suitable form (e.g., oral or buccal administration). When administered orally, the compound of formula I may be prepared in the form of a hard or soft capsule, including gelatin encapsulation form, sachet, or lozenge, in solution or suspension, as a mixture with excipients suitable for the manufacture of oral dosage forms such as tablets. Suspensions for oral administration may be prepared according to any method known to those skilled in the art. For example, the suspension may be an oil suspension in which the compound of any one of formulae (I)-(VI) is suspended in a liquid suspension containing, for example, a vegetable oil such as olive oil, sesame oil, or coconut oil. The liquid suspension may also contain a mineral oil.

[0112] The compositions may also be administered topically, for example, for application to the skin in the form of, for example, creams, pastes, lotions, gels, ointments, compresses, poultices, salves, skin patches, and the like, or for ophthalmic application in the form of, for example, eye drops, lotion or gel formulations.

[0113] The composition may also be administered parenterally (e.g., intravenously). Intravenous dosage forms include, but are not limited to, bolus injection and infusion. In some embodiments, intravenous dosage forms are sterile or can be sterilized before administration to a subject, since they usually bypass the subject's natural defense mechanism against contaminants. Examples of intravenous dosage forms include, but are not limited to, water for injection USP; aqueous vehicles such as, but are not limited to, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles such as, but are not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; non-aqueous vehicles such as, but are not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[0114] They may also be administered in easily flowable forms, such as solutions, emulsions and suspensions, for example, for intralesional injection, rectally, for example, as enemas or suppositories, or intranasally, for example, as nasal sprays or aerosols. Macrocrystalline powders may also be formulated for inhalation, for example, for delivery to the nose, nasal cavity, pharynx or lungs. Transdermal compositions / devices and pessaries may also be used to deliver the compounds of the present invention. The compositions may further comprise agents that enhance the delivery of the compound having formula I (or other active agents), such as, for example, liposomes, polymers or copolymers (e.g., branched polymers).

[0115] The pharmaceutical composition of the present invention may further comprise one or more additives. Additives known in the art include, for example, detackifiers, antifoaming agents, buffers, antioxidants (e.g., ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, malic acid, fumaric acid, potassium pyrosulfite, sodium bisulfite, sodium pyrosulfite, and tocopherols such as α-tocopherol (vitamin E)), preservatives, chelating agents, viscosity modifiers, tonicifiers, flavoring agents, coloring agents, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof. The amount of such additives can be easily determined by those skilled in the art according to the specific properties desired, and can be formulated so that the compound having formula I is stabilized, for example, not reduced by the antioxidant additives.

[0116] The additive may also include a thickening agent. Suitable thickening agents may be those known and used in the art, such as, for example, pharma- ceutically acceptable polymeric materials and inorganic thickening agents. Exemplary thickening agents for use in the pharmaceutical compositions include polyacrylic acid resins, polyacrylic acid copolymer resins, such as polyacrylic acid and polyacrylic acid / methacrylic acid resins; cellulose and cellulose derivatives, including alkyl celluloses (e.g., methyl cellulose, ethyl cellulose, and propyl cellulose); hydroxyalkyl celluloses (e.g., hydroxypropyl cellulose, and hydroxypropyl alkyl celluloses, such as hydroxypropyl cellulose and hydroxypropyl methyl cellulose); acylated celluloses (e.g., cellulose acetate, cellulose acetate phthalate, cellulose acetate succinate, and hydroxypropyl ethyl cellulose phthalate). and salts thereof, such as sodium-carboxymethylcellulose; polyvinylpyrrolidones, such as poly-N-vinylpyrrolidone and vinylpyrrolidone copolymers, such as vinylpyrrolidone-vinyl acetate copolymers; polyvinyl resins, such as polyvinyl acetate and alcohols, and other polymeric materials, such as gum tragacanth, gum arabic, alginates, such as alginic acid, and salts thereof, such as sodium alginate; inorganic thickeners, such as attapulgite, bentonite, and silicates, including hydrophilic silicon dioxide products, such as alkylated (e.g., methylated) silica gels, especially colloidal silicon dioxide products.

[0117] A thickening agent, such as those listed above, may be included, for example, to provide a sustained release effect. However, if oral administration is intended, the use of a thickening agent may not be necessary. On the other hand, for example, if topical application is anticipated, the use of a thickening agent is suggested.

[0118] Although the dosage of any one of the compounds of formulas (I) to (VI) varies according to the activity and / or toxicity of the particular compound, the condition to be treated, and the physical form of the pharmaceutical composition used for administration, it can be said that, as a guideline, a dosage selected in the range of 1 to 2000 mg / kg body weight per day is often appropriate. Methods for determining appropriate dosages are well known to those skilled in the art. EXAMPLES

[0119] Materials and equipment All solvents used were commercially available and were used without purification. Reactions were typically performed using anhydrous solvents under an inert atmosphere of nitrogen. Proton NMR spectra were recorded using a Bruker 400MHz NMR instrument. Deuterated solvents (DMSO-d6) typically contained 0.03%-0.05% (v / v) tetramethylsilane, which was used as the reference signal (δ set at 0.00 for 1H). LCMS analysis was performed using a Shimadzu LCMS consisting of a UFLC 20-AD and an LCMS 2020MS detector. The column used was a Shim-pack XR-ODS, 2.2 μm, 3.0 × 50 mm. The instrument uses reversed-phase conditions (acetonitrile / water containing 10 mM ammonium bicarbonate).

[0120] Provided below are definitions of terms used in the Schemes that follow and elsewhere in this specification.

[0121] [Table 1]

[0122] Example 1 Synthesis of N-(4-[[(1S)-1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]-1,2,3-thiadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide and N-(4-[[(1R)-1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]-1,2,3-thiadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide (16) [ka]

[0123] Step 1: Ethyl 5-[5-(trifluoromethyl)pyridine-3-amido]-1,2,3-thiadiazole-4-carboxylate A mixture of ethyl 5-amino-1,2,3-thiadiazole-4-carboxylate (1.50 g, 8.66 mmol) and 5-(trifluoromethyl)pyridine-3-carboxylic acid (1.99 g, 10.4 mmol) in pyridine (40 mL) was stirred and POCl3 (11.0 mL, 113 mmol) was added dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred at 25° C. under nitrogen atmosphere for 2 h. The reaction mixture was poured into ice water (100 mL). The mixture was adjusted to pH 8 basic with saturated NaHCO3 (aq) at 0° C. The resulting mixture was extracted with CH2Cl2 (600 ml×3). The combined organic layers were washed with 1 M HCl (600 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (2:1) to give ethyl 5-[5-(trifluoromethyl)pyridine-3-amide]-1,2,3-thiadiazole-4-carboxylate (1.10 g, 37%) as a yellow solid. LCMS (ES, m / z): 347 [M+H] + .

[0124] Step 2: 5-[5-(trifluoromethyl)pyridine-3-amido]-1,2,3-thiadiazole-4-carboxylic acid To a solution of ethyl 5-[5-(trifluoromethyl)pyridine-3-amide]-1,2,3-thiadiazole-4-carboxylate (1.10 g, 3.17 mmol) in EtOH (60 mL) was added NaOH (8 mol / L aq) (60 mL). The resulting mixture was stirred at 25° C. for 2 h. The mixture was acidified to pH 3 with 1 M HCl at 0° C. The volatiles were evaporated. The solid was collected by filtration, washed with water (100 mL) and dried under infrared light. This gave 5-[5-(trifluoromethyl)pyridine-3-amide]-1,2,3-thiadiazole-4-carboxylic acid (1 g, 96%) as a white solid. LCMS (ES, m / z): 319 [M+H] + .

[0125] Step 3: tert-Butyl N-[1-(4-chlorophenyl)-2-oxo-2-(pyrrolidin-1-yl)ethyl]carbamate A mixture of [(tert-butoxycarbonyl)amino](4-chlorophenyl)acetic acid (500 mg, 1.75 mmol), HOBT (476 mg, 3.52 mmol), EDCI (674 mg, 3.52 mmol), and DIEA (701 mg, 5.42 mmol) in DMF (5 mL) was stirred and pyrrolidine (200 mg, 2.81 mmol) was added. The resulting mixture was stirred at 26° C. for 2 h. The resulting mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (50 ml), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on C column. 18 Purification by reverse flash chromatography under the following conditions: silica gel, 80 g, 20-35 μm; mobile phase: water and ACN containing 0.1% FA (gradient 0%-80% in 50 min); detector: UV 254 nm. This gave tert-butyl N-[1-(4-chlorophenyl)-2-oxo-2-(pyrrolidin-1-yl)ethyl]carbamate (400 mg, 64%) as a yellow oil. LCMS (ES, m / z): 339, 341 [M+H] + .

[0126] Step 4: tert-butyl N-[1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamate A solution of tert-butyl N-[1-(4-chlorophenyl)-2-oxo-2-(pyrrolidin-1-yl)ethyl]carbamate (300 mg, 0.84 mmol) in THF (10 mL) was stirred and DIBA1-H (10 mL, 9.92 mmol) (1 mol / L hexane solution) was added dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred at 25° C. for 3 hours. The resulting mixture was poured into water (100 mL) and extracted with EtOAc (100 mL×3 times). The combined organic layer was washed with brine (200 ml), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column: C 18 Purification was performed by reverse flash chromatography using the following conditions: silica gel, 80 g, 20-35 μm; mobile phase: water and ACN containing 0.1% FA (gradient 0%-100% in 30 min); detector: UV 254 nm. The product fractions were concentrated in vacuo to give tert-butyl N-[1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamate (150 mg, 25%) as a yellow oil. LCMS (ES, m / z): 325, 327 [M+H] + .

[0127] Step 5: 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethanamine dihydrochloride To a stirred solution of tert-butyl N-[1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamate (180 mg, 0.55 mmol) in 1,4-dioxane (1 mL), a solution of HCl (gas) in 1,4-dioxane (4 M, 2 mL) was added at 0° C. The resulting mixture was stirred at 26° C. for 1 h. The mixture was concentrated in vacuo to give 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethanamine dihydrochloride (150 mg, 86%) as a white solid. The product was used in the next step without further purification. LCMS (ES, m / z) 225, 227 [M-2HCl+H] + .

[0128] Step 6: N-(4-[[(1S)-1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]-1,2,3-thiadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide and N-(4-[[(1R)-1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]-1,2,3-thiadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide (16) A mixture of 5-[5-(trifluoromethyl)pyridine-3-amide]-1,2,3-thiadiazole-4-carboxylic acid (157 mg, 0.48 mmol) in DMF (3 mL) was stirred and HATU (372 mg, 0.96 mmol), DIEA (316 mg, 2.39 mmol), and 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethanamine dihydrochloride (150 mg, 0.48 mmol) were added. The resulting mixture was stirred at 26° C. for 2 h. The resulting mixture was poured into water (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column: C 18Purification was performed by reverse flash chromatography using the following conditions: silica gel, 40 g, 20-35 μm; mobile phase, water with 0.1% FA and ACN (gradient 0%-80% in 30 min); detector: UV 254 nm. The product fractions were concentrated under vacuum to give the racemic product. The racemate was separated by prep chiral HPLC using the following conditions: column: CHIRAKPAK IG, 2 × 25 cm, 5 μm; mobile phase A: Hex (0.1% TEA), mobile phase B: EtOH; flow rate: 20 mL / min; gradient: 30B-30B in 13.5 min; 220 / 254 nm; RT1: 6.837; RT2: 11.035. The product fractions were concentrated under vacuum and then dissolved in ACN (5 mL) and HO (5 mL). The mixture was lyophilized to give the first eluting isomer, N-(4-[[(1S)-1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]-1,2,3-thiadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide (11.3 mg, 4%) as a white solid, followed by the second eluting isomer, N-(4-[[(1R)-1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl]-1,2,3-thiadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide (12.4 mg, 5%) as a white solid.

[0129] First eluting isomer: 1 H-NMR (DMSO-d6, 400 MHz) δ(ppm): 10.46 (br s, 1H), 9.47 (br s, 2H), 9.10 (s, 1H), 8.59 (s, 1H), 7.65 (d, J = 6.8 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 5.78 (br s, 1H), 3.85-3.38 (m, 6H), 2.05-1.98 (m, 4H). LCMS(ES,m / z):525,527[M+H] + .

[0130] Second eluting isomer (16): 1H-NMR (DMSO-d6, 400 MHz) δ(ppm): 10.46(br s, 1H), 9.51-9.38 (m, 2H), 9.10 (s, 1H), 8.59 (s, 1H), 7.64 (d, J = 7.6 Hz, 2H), 7.48 (d, J = 2 Hz, 2H), 5.78 (br s, 1H), 3.84-3.40 (m, 6H), 2.02-1.90 (m, 4H). LCMS(ES,m / z):525,527[M+H] + .

[0131] Example 2 Synthesis of 2-(4-chlorobenzenesulfonamido)-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide (17) [ka] Step 1: 2-nitro-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide A mixture of 2-nitro-4-(trifluoromethyl)benzoic acid (5.00 g, 21.3 mmol) and HATU (12.0 g, 31.6 mmol) in DMF (30 mL) was stirred, and DIEA (10.2 mL, 61.9 mmol) and 4-phenylthiazol-2-amine (4.00 g, 22.7 mmol) were added at 0° C. The resulting mixture was stirred at 25° C. for 2 h. The mixture was diluted with ice water (100 mL) and extracted with DCM (10 mL×3). The combined organic layer was washed with brine (100 ml×3) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give 2-nitro-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide (2.00 g, 23%) as a light brown solid. LCMS (ES, m / z): 394 [M+H] + .

[0132] Step 2: 2-Amino-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide 2-Nitro-N-(4-phenyl-thiazol-2-yl)-4-(trifluoromethyl)benzamide (2.00 g, 5.08 mmol) and Pd / C (200 mg, 10%) in MeOH (50 mL) were stirred under hydrogen atmosphere at 25° C. for 2 h. The solids were removed by filtration and the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase column (column: C 18 Purification by silica gel; mobile phase: water containing FA (0.1%) and ACN (gradient 10% to 50% in 40 min); detector: UV254 / 220 nm) gave 2-amino-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide (1.07 g, 54%) as a dark yellow solid. LCMS (ES, m / z): 364 [M+H] + .

[0133] Step 3: 2-(4-chlorobenzenesulfonamido)-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide (17) A mixture of 2-amino-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide (100 mg, 0.27 mmol) and 4-chlorobenzene-1-sulfonyl chloride (290 mg, 1.37 mmol) in pyridine (5 mL) was stirred at 60° C. for 5 h. The mixture was cooled to room temperature, diluted with ice water (20 mL) and extracted with DCM (10 mL×3). The combined organic layers were washed with brine (30 ml) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography: 18Purification was performed by reverse flash chromatography using the following conditions: silica gel, 80 g, 20-35 μm; mobile phase: water (0.1% FA) and ACN (0%-100% in 30 min; detector: UV 254 / 220 nm. The collected fractions were lyophilized to give 2-(4-chlorobenzenesulfonamido)-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide (23.1 mg, 16%) as a white solid.

[0134] 1 H-NMR (400 MHz, DMSO-d6) δ(ppm):12.89 (br s, 1H), 10.44 (br s, 1H), 7.96-7.91 (m, 3H), 7.79-7.66 (m, 4H), 7.57 (d, J = 8.4 Hz, 2H), 7.49-7.45 (m, 3H), 7.38-7.34 (m, 1H). LCMS(ES,m / z):538,540[M+H] + .

[0135] Example 3 Synthesis of 5-(3-chlorobenzamido)-N-[2-(3-chlorophenyl)propan-2-yl]-1,2,3-thiadiazole-4-carboxamide (18) [ka]

[0136] Step 1: Ethyl 5-(3-chlorobenzamido)-1,2,3-thiadiazole-4-carboxylate To a mixture of 3-chlorobenzoic acid (2.20 g, 13.2 mmol) and HATU (5.00 g, 13.2 mmol) in DMF (60 mL) was added ethyl 5-amino-1,2,3-thiadiazole-4-carboxylate (2.00 g, 11.0 mmol) and DIEA (5.90 mL, 32.9 mmol) dropwise at 0° C. The reaction mixture was stirred at room temperature for 3 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (50 mL×3 times). The combined organic layers were washed with brine (30 mL×2 times), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give ethyl 5-(3-chlorobenzamido)-1,2,3-thiadiazole-4-carboxylate (2.50 g, 73%) as a white solid. LCMS(ES,m / z):312,314[M+H] + .

[0137] Step 2: 5-(3-chlorobenzamido)-1,2,3-thiadiazole-4-carboxylic acid A mixture of ethyl 5-(3-chlorobenzamido)-1,2,3-thiadiazole-4-carboxylate (2.50 g, 7.62 mmol) and NaOH (0.60 g, 15.0 mmol) in HO (20 mL) and EtOH (30 mL) was stirred at 25° C. for 16 h. The resulting mixture was partially concentrated under reduced pressure. The mixture was acidified to pH 3 with HCl (1N). The precipitated solid was collected by filtration, washed with water (10 mL) and dried under vacuum to give 5-(3-chlorobenzamido)-1,2,3-thiadiazole-4-carboxylic acid (2.00 g, 88%) as a white solid. LCMS (ES, m / z): 284, 286 [M+H] + .

[0138] Step 3: 5-(3-chlorobenzamido)-N-[2-(3-chlorophenyl)propan-2-yl]-1,2,3-thiadiazole-4-carboxamide (18) A mixture of 5-(3-chlorobenzamido)-1,2,3-thiadiazole-4-carboxylic acid (200 mg, 0.63 mmol) and HATU (361 mg, 0.94 mmol) in DMF (5 mL) was stirred and 2-(3-chlorophenyl)propan-2-amine (129 mg, 0.76 mmol) and DIEA (315 μL, 1.90 mmol) were added dropwise at 0° C. The resulting mixture was stirred at 25° C. for 1 h. The mixture was diluted with water (15 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (15 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EtOAc (1:1). The crude product was purified by prep HPLC using the following conditions: Column: XBridge Shield RP18 OBD Column, 30×150 mm, 5 μm; Mobile phase, A: water (10 mmol / L NH4HCO3) and B: ACN (30%-60% in 7 min); Detector: UV 254 nm. The product fraction (RT: 6.44 min) was lyophilized to give 5-(3-chlorobenzamido)-N-[2-(3-chlorophenyl)propan-2-yl]-1,2,3-thiadiazole-4-carboxamide (53.6 mg, 19%) as a white solid. 1 H-NMR (DMSO, 400 MHz) δ(ppm):12.13 (s, 1H), 9.21 (s, 1H), 7.90 (br s, 1H), 7.85-7.75(m, 2H), 7.70-7.59 (m, 1H), 7.52 (s, 1H), 7.50-7.45 (m, 1H), 7.38-7.34 (m, 1H), 7.28-7.27 (m, 1H), 1.79 (s, 6H). LCMS(ES,m / z):435,437[M+H] + .

[0139] Example 4 Synthesis of N-[(4-chlorophenyl)methyl]-5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxamide (24) [ka]

[0140] Step 1: Ethyl 5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylate A mixture of 3-(trifluoromethyl)benzoic acid (177 mg, 0.93 mmol) and HATU (444 mg, 1.16 mmol) in DMF (9 mL) was stirred and ethyl 5-amino-1,2,3-thiadiazole-4-carboxylate (150 mg, 0.87 mmol) and DIEA (386 μL, 2.33 mmol) were added dropwise at 0° C. The resulting mixture was stirred at 25° C. for 16 h. The reaction was quenched by adding water (10 mL) at room temperature. The solid was collected by filtration, washed with water (7 mL×3 times), and dried under UV light to give ethyl 5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylate (160 mg, 50%) as a yellow solid. LCMS (ES, m / z): 346 [M+H] + .

[0141] Step 2: 5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylic acid A mixture of NaOH (66 mg, 1.65 mmol) in EtOH (3 mL) and HO (3 mL) was stirred and ethyl 5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylate (160 mg, 0.46 mmol) was added in portions at 0° C. The resulting mixture was stirred at 25° C. for 3 h. The resulting mixture was partially concentrated under reduced pressure. The mixture was acidified to pH 6 with HCl (1N). The precipitated solid was collected by filtration, washed with water (10 mL) and dried under UV light to give 5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylic acid (100 mg, 68%) as an off-white solid. LCMS (ES, m / z): 318 [M+H] + .

[0142] Step 3: N-[(4-chlorophenyl)methyl]-5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxamide (24) A mixture of 5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylic acid (100 mg, 0.31 mmol) in DMF (3 mL) was stirred and HATU (170 mg, 0.44 mmol), 1-(4-chlorophenyl)methanamine (51 mg, 0.36 mmol), and DIEA (150 μL, 0.89 mmol) were added at 0° C. The resulting mixture was stirred at 25° C. for 4 h. The mixture was diluted with water (15 mL) and extracted with CHCl (10 mL×3). The combined organic layers were washed with brine (15 ml), dried over anhydrous NaSO, and concentrated under reduced pressure. The crude product was purified by prep HPLC, column: XBridge Prep C 18 Purification was performed using an OBD Column, 5 μm, 19 × 150 mm; mobile phase, A: water (containing 0.05% TFA) and ACN (55% to 85% in 7 min); detector: UV 254 nm. The product fraction (RT: 6.68 min) was lyophilized to give N-[(4-chlorophenyl)methyl]-5-[3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxamide (33 mg, 24%) as an off-white solid.

[0143] 1 H-NMR (DMSO, 400 MHz) δ(ppm):9.42 (br s, 1H), 8.04-8.00 (m, 2H), 7.95-7.90 (m, 1H), 7.76-7.72 (m, 1H), 7.69-7.47 (m, 1H), 7.44-7.29 (m, 4H), 4.52 (d, J = 6.4 Hz, 2H). LCMS(ES,m / z):441,443[M+H] + .

[0144] Example 5 Synthesis of N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-[2-chloro-3-(trifluoromethyl)benzamide]-1,2,3-thiadiazole-4-carboxamide (25) [ka] Step 1: 5-chloro-N-[(4-methoxyphenyl)methyl]-2,3-dihydro-1H-inden-2-amine A mixture of 5-chloro-2,3-dihydro-1H-inden-2-one (200 mg, 1.20 mmol), 4-methoxybenzylamine (247 mg, 1.80 mmol) in DCM (5 mL) was stirred and AcOH (0.1 mL) and STAB (763 mg, 3.60 mmol) were added. The reaction mixture was stirred at 25 °C for 16 h. The resulting mixture was diluted with water (10 mL) and extracted with CHCl (10 mL x 3). The combined organic layers were washed with brine (10 ml), dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give 5-chloro-N-[(4-methoxyphenyl)methyl]-2,3-dihydro-1H-inden-2-amine (140 mg, 41%) as a yellow solid. LCMS(ES,m / z):288,290[M+H] + .

[0145] Step 2: 5-Chloro-2,3-dihydro-1H-inden-2-amine A mixture of 5-chloro-N-[(4-methoxyphenyl)methyl]-2,3-dihydro-1H-inden-2-amine (120 mg, 0.42 mmol) and (NH4)2Ce(NO3)6 (86 mg, 0.16 mmol) in ACN (2 mL) and H2O (0.5 mL) was stirred at 25° C. for 16 h under nitrogen atmosphere. The resulting mixture was diluted with water (5 mL) and extracted with EtOAc (5 mL×3). The combined organic layers were washed with brine (10 ml), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography: 18Purification was carried out by reverse flash chromatography under the following conditions: silica gel (80 g, 20 μm); mobile phase: water (containing 0.05% TFA), ACN (0% to 80% in 30 min); detector: UV 254 nm. The collected fractions were concentrated to give 5-chloro-2,3-dihydro-1H-inden-2-amine (30 mg, 42%) as a yellow solid. LCMS (ES, m / z): 168, 170 [M+H] + .

[0146] Step 3: Ethyl 5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylate A mixture of ethyl 5-amino-1,2,3-thiadiazole-4-carboxylate (100 mg, 0.52 mmol) in DCM (5 mL) was stirred and added with NaH (24 mg, 0.60 mmol, 60%) at 0° C. After stirring for 10 min, 2-chloro-3-(trifluoromethyl)benzoyl chloride (151 mg, 0.59 mmol) in DCM (1 mL) was added dropwise at 0° C. to the above mixture. The resulting mixture was stirred at 25° C. under nitrogen atmosphere for 16 h. The mixture was then poured into water (5 mL) and extracted with EtOAc (5 mL×3). The combined organic layers were washed with brine (8 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (2:1) to give ethyl 5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylate (120 mg, 54%) as a white solid. LCMS (ES, m / z): 380, 382 [M+H] + .

[0147] Step 4: 5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylic acid A mixture of ethyl 5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylate (120 mg, 0.40 mmol) and NaOH (32 mg, 0.81 mmol) in EtOH (3 mL) and HO (1 mL) was stirred at 25 °C for 16 h. The resulting mixture was acidified to pH 5 with HCl (1N) and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (8 mL x 2), dried over anhydrous NaSO and concentrated under reduced pressure. The residue was purified by reverse flash chromatography (column: C 18 Purification was performed using silica gel; mobile phase: water (containing 0.1% TFA) and ACN (0% to 90% in 30 min; detector: UV 254 nm). The collected fractions were concentrated to give 5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylic acid (100 mg, 69%) as a white solid. LCMS (ES, m / z): 352, 354 [M+H] + .

[0148] Step 5: N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-[2-chloro-3-(trifluoromethyl)benzamide]-1,2,3-thiadiazole-4-carboxamide (25) A mixture of 5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxylic acid (30 mg, 0.08 mmol), HATU (44 mg, 0.12 mmol), 5-chloro-2,3-dihydro-1H-inden-2-amine (15 mg, 0.09 mmol), and DIEA (29 mg, 0.23 mmol) in DMF (3 mL) was stirred at 25° C. for 16 h. The resulting mixture was diluted with water (5 mL) and extracted with EtOAc (5 mL×3). The combined organic layers were washed with brine (10 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on C column. 18Purification was performed by reverse flash chromatography using silica gel (40 g, 20-35 μm); mobile phase, A: water (containing 0.1% FA), B: ACN (0%-60% in 30 min); detector: UV 254 nm. The product fraction was lyophilized to give N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-[2-chloro-3-(trifluoromethyl)benzamido]-1,2,3-thiadiazole-4-carboxamide (12 mg, 29%) as an off-white solid.

[0149] 1 H-NMR (CD3OD, 400 MHz) δ(ppm): 8.09-8.07 (m, 2H), 7.75-7.71 (m, 1H), 7.26-7.17 (m, 3H), 4.99-4.91 (m, 1H), 3.40-3.38 (m, 2H), 3.14-3.01 (m, 2H). LCMS(ES,m / z):501,503[M+H] + .

[0150] Example 6 Synthesis of (S)-N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxamide (first eluting isomer) and (R)-N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxamide (second eluting isomer) (29) [ka]

[0151] Step 1: Ethyl 5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxylate A mixture of ethyl 5-amino-1,2,3-thiadiazole-4-carboxylate (400 mg, 2.31 mmol) and 5-(trifluoromethyl)pyridine-3-carboxylic acid (530 mg, 2.77 mmol) in pyridine (20 mL) was stirred and POCl3 (2.80 mL, 30.0 mmol) was added dropwise at 0°C. The resulting mixture was stirred at 25°C for 2 h. The resulting mixture was concentrated under reduced pressure. The residue was diluted with ice water (20 mL), adjusted to pH 8 basic with saturated NaHCO3 (aq), and extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine (100 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give ethyl 5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxylate (610 mg, 71%) as a yellow solid. LCMS (ES, m / z): 347 [M+H] + .

[0152] Step 2: 5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxylic acid A mixture of ethyl 5-[5-(trifluoromethyl)pyridine-3-amide]-1,2,3-thiadiazole-4-carboxylate (600 mg, 1.73 mmol) in NaOH (8 M) (20 mL) and EtOH (20 mL) was stirred at 25° C. for 2 h. The resulting mixture was partially concentrated under reduced pressure. The mixture was acidified to pH 3 with 1 M HCl at 0° C. The solid was collected by filtration, washed with water (3×20 mL) and dried under infrared light. This gave 5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxylic acid (500 mg, 83%) as a white solid. LCMS (ES, m / z): 319 [M+H] + .

[0153] Step 3: (S)—N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxamide (first eluting isomer), and (R)—N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxamide (second eluting isomer) (29) A mixture of 5-[5-(trifluoromethyl)pyridine-3-amide]-1,2,3-thiadiazole-4-carboxylic acid (70 mg, 0.22 mmol) in DMF (2 mL) was stirred and HATU (126 mg, 0.33 mmol), DIEA (0.11 mL, 0.66 mmol), and 5-chloro-2,3-dihydro-1H-inden-2-amine (44 mg, 0.26 mmol) were added at 0° C. The resulting mixture was stirred at 25° C. for 2 h. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (50 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (1:2) to give the racemic product. The racemate was separated by chiral prep HPLC under the following conditions: Column: CHIRAKPAK AD-H SFC, 5 x 25 cm, 5 μm; Mobile phase A: Hex (0.1% IPA), Mobile phase B: EtOH; Flow rate: 20 mL / min; Gradient: 5B to 5B in 45 min; 254 / 220 nm; RT1: 19.839; RT2: 33.398. The collected fractions were concentrated under reduced pressure to give (S)-N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxamide (first eluting isomer) (3.7 mg, 4%) as a white solid, and (R)-N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-5-(5-(trifluoromethyl)nicotinamide)-1,2,3-thiadiazole-4-carboxamide (second eluting isomer) (5.3 mg, 5%) as a white solid, respectively.

[0154] First eluting isomer:1 H-NMR (DMSO, 400 MHz) δ(ppm): 12.64 (br s, 1H), 9.70-9.62 (m, 1H), 9.39 (s, 1H), 9.32 (s, 1H), 8.68 (s, 1H), 7.32-7.21 (m, 3H), 4.95-4.89 (m, 1H), 3.28-3.22 (m, 2H), 3.17-3.01 (m, 2H). LCMS(ES,m / z):468[M+H] + .

[0155] Second eluting isomer: 1 H-NMR (DMSO, 400 MHz) δ(ppm): 12.64 (br s, 1H), 9.74-9.68 (m, 1H), 9.39 (s, 1H), 9.32 (s, 1H), 8.68 (s, 1H), 7.32-7.21 (m, 3H), 4.95-4.90 (m, 1H), 3.28-3.23 (m, 2H), 3.17-3.01 (m, 2H). LCMS(ES,m / z):468[M+H] + .

[0156] Example 7 Synthesis of 5-[2-chloro-3-(trifluoromethyl)benzamido]-N-[(4-chlorophenyl)methyl]-3-methyl-1,2-thiazole-4-carboxamide (34) [ka]

[0157] Step 1: Methyl 5-(2-chloro-3-(trifluoromethyl)benzamido)-3-methylisothiazole-4-carboxylate A stirred solution of 2-chloro-3-(trifluoromethyl)benzoic acid (240 mg, 1.07 mmol) in DCM (3 mL) was added dropwise at 0° C. with (COCl)2 (5 mL) and DMF (0.01 mL). The resulting mixture was stirred at room temperature (25° C.) for 16 h. The resulting mixture was concentrated under reduced pressure. The residue was redissolved in DCM (5 mL). This freshly prepared acyl chloride solution was then added dropwise to a stirred mixture of 5-amino-3-methylisothiazole-4-carboxylate (140 mg, 0.81 mmol) and TEA (200 μL, 1.43 mmol) in DCM (10 mL) at 0° C. The resulting mixture was stirred at 25° C. for 6 h. The mixture was poured into water (10 mL) and extracted with CH2Cl2 (10 mL×3). The combined organic layers were washed with brine (15 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by prep TLC (eluted with PE / EtOAc 1:1) to give methyl 5-(2-chloro-3-(trifluoromethyl)benzamido)-3-methylisothiazole-4-carboxylate (100 mg, 32%) as a yellow solid. LCMS (ES, m / z): 379, 381 [M+H] + .

[0158] Step 2: 5-[2-chloro-3-(trifluoromethyl)benzamido]-3-methyl-1,2-thiazole-4-carboxylic acid A mixture of methyl 5-(2-chloro-3-(trifluoromethyl)benzamido)-3-methylisothiazole-4-carboxylate (100 mg, 0.26 mmol) and LiOH (7 mg, 0.29 mmol) in THF (2 mL) and HO (2 mL) was stirred at 60° C. for 16 h. The mixture was cooled to room temperature, acidified to pH 4 with HCl (1N), and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (15 ml), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by reverse flash chromatography (column: C 18Purification was performed by silica gel; mobile phase: ACN / water, gradient 0% to 80% in 30 min; detector: UV 254 nm). The collected fractions were concentrated to give 5-[2-chloro-3-(trifluoromethyl)benzamido]-3-methyl-1,2-thiazole-4-carboxylic acid (60 mg, 63%) as a white solid. LCMS (ES, m / z): 365, 367 [M+H] + .

[0159] Step 3: 5-[2-chloro-3-(trifluoromethyl)benzamido]-N-[(4-chlorophenyl)methyl]-3-methyl-1,2-thiazole-4-carboxamide (34) To a stirred solution of 5-[2-chloro-3-(trifluoromethyl)benzamido]-3-methyl-1,2-thiazole-4-carboxylic acid (40 mg, 0.11 mmol) in DCM (5 ml) was added (COCl)2 (63 mg, 0.49 mmol). The reaction mixture was stirred at 25° C. for 5 h. The resulting mixture was concentrated under reduced pressure. The residue was redissolved in DCM (3 mL) and this freshly prepared acyl chloride solution was added dropwise to a stirred mixture of 1-(4-chlorophenyl)methanamine (19 mg, 0.13 mmol) and TEA (40 μL, 0.30 mmol) in DCM (5 mL) at 0° C.

[0160] The resulting mixture was stirred at 25° C. for an additional 16 h. The mixture was diluted with water (15 mL) and extracted with CH2Cl2 (10 mL x 3). The combined organic layers were washed with brine (15 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by prep HPLC (column: XBridge Prep C 18 Purification was performed using an OBD Column, 19×150 mm, 5 μm; mobile phase, A: water (containing 0.05% TFA) and B: ACN (50%-83% in 7 min; detector: UV 254 nm). The collected fraction (RT: 6.54 min) was lyophilized to give 5-[2-chloro-3-(trifluoromethyl)benzamido]-N-[(4-chlorophenyl)methyl]-3-methyl-1,2-thiazole-4-carboxamide (28.2 mg, 52%) as a white solid.

[0161] 1 H-NMR (CD3OD, 400 MHz) δ(ppm): 8.02-8.00 (m, 1H), 7.95-7.93 (m, 1H), 7.69-7.65 (m, 1H), 7.39- 7.34 (m, 4H), 4.56 (s, 2H), 2.57 (s, 3H). LCMS(ES,m / z):488,490[M+H] + .

[0162] Example 8 Synthesis of 2-[2-chloro-3-(trifluoromethyl)benzamido]-N-[(4-chlorophenyl)methyl]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxamide (35) [ka]

[0163] Step 1: 2-amino-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylate ethyl A mixture of oxan-4-one (2.84 g, 28.4 mmol) and ethyl cyanoformate (3.60 g, 34.1 mmol), TEA (6.30 mL, 43.1 mmol) and sulfur (0.90 g, 26.6 mmol) in EtOH (20 mL) was stirred at 55° C. for 5 h. The reaction mixture was cooled to room temperature, the solids were filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give ethyl 2-amino-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylate (2.00 g, 31%) as a white solid. LCMS (ES, m / z): 228 [M+H] + .

[0164] Step 2: 2-[2-chloro-3-(trifluoromethyl)benzamido]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylate ethyl A solution of 2-chloro-3-(trifluoromethyl)benzoic acid (325 mg, 1.38 mmol) and DMF (0.1 mL) in SOCl2 (10 mL) was stirred at 80 °C for 5 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was redissolved in DCM (5 mL). The freshly prepared acyl chloride solution was then added dropwise to a mixture of ethyl 2-amino-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylate (305 mg, 1.21 mmol) and TEA (335 μL, 2.42 mmol) in DCM (10 mL) with stirring at 0 °C. The resulting mixture was stirred at 25 °C for an additional 3 h. The reaction mixture was poured into ice water (10 mL) and extracted with CHCl2 (10 mL x 3). The combined organic layers were washed with brine (5 mL x 2), dried over anhydrous NaSO4, and concentrated under reduced pressure. The residue was purified by prep TLC (CH2Cl2 / MeOH 15:1) to give ethyl 2-[2-chloro-3-(trifluoromethyl)benzamido]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylate (200 mg, 38%) as a yellow solid. LCMS (ES, m / z): 434, 436 [M+H] + .

[0165] Step 3: 2-[2-chloro-3-(trifluoromethyl)benzamido]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylic acid A mixture of ethyl 2-[2-chloro-3-(trifluoromethyl)benzamide]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylate (200 mg, 0.46 mmol) and NaOH (33 mg, 0.83 mmol) in HO (3 mL) and EtOH (3 mL) was stirred at 80 °C for 2 h. The mixture was cooled to room temperature, acidified to pH 3 with HCl (1N aq.), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (5 ml x 2), dried over anhydrous NaSO, and concentrated under reduced pressure to give 2-[2-chloro-3-(trifluoromethyl)benzamide]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylic acid (150 mg, 80%) as a yellow solid. LCMS (ES, m / z): 406, 408 [M+H]+ .

[0166] Step 4: 2-[2-chloro-3-(trifluoromethyl)benzamido]-N-[(4-chlorophenyl)methyl]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxamide (35) To a mixture of 2-[2-chloro-3-(trifluoromethyl)benzamide]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxylic acid (100 mg, 0.22 mmol) and HATU (101 mg, 0.27 mmol) in DMF (3 mL) was added 1-(4-chlorophenyl)methanamine (37 mg, 0.27 mmol) and DIEA (110 μL, 0.67 mmol) at 25° C. The reaction mixture was stirred at 25° C. for 16 h. The mixture was diluted with water (15 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (15 ml), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by prep HPLC (column: XBridge Prep C 18 Purification was performed using an OBD Column, 19×150 mm, 5 μm; mobile phase, A: water (10 mmol / L NH4HCO3) and B: ACN (22%-52% in 7 min); detector: UV 254 nm. The product fraction (RT 6.15 min) was lyophilized to give 2-[2-chloro-3-(trifluoromethyl)benzamido]-N-[(4-chlorophenyl)methyl]-4H,6H,7H-thieno[3,2-c]pyran-3-carboxamide (8.6 mg, 7%) as a yellow solid.

[0167] 1H-NMR (DMSO, 400 MHz) δ(ppm):11.80 (s, 1H), 8.30-8.27 (m, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 7.6 Hz, 1H), 7.72-7.68 (m, 1H), 7.38-7.32 (m, 4H), 4.71 (s, 2H), 4.41 (d, J = 6.4 Hz, 2H), 3.89-3.87 (m, 2H), 2.80 (s, 2H). LCMS(ES,m / z):529,531[M+H] + .

[0168] Example 9 USP36 inhibition biochemical assay protocol USP36 enzyme assays were performed in a buffer containing 20 mM Tris-HCl (Corning 46-031-CM) at pH 8.0, 3 mM 2-mercaptoethanol (Sigma, M6250), 0.03% BGG (Sigma, G7516), and 0.01% Triton X-100 (Sigma, 93443) (final volume: 6 μL). Test compounds were serially diluted in DMSO (Sigma, G7516) to obtain a 10-point 3-fold series. Nanoliter amounts were pre-aliquoted into a 1536 assay plate (Corning, 9110BC) for a concentration response range of 26.6 μM to 1.35 nM. 3 μL of 2× enzyme was added to the assay plate and pre-incubated with compound for 30 min, after which 3 μL of 2× substrate was added to start the reaction (final concentrations of human USP36(81-461) 2 nM and Ub-Rh110MP (UbiQ, UbiQ-126) 25 nM). Enzyme and substrate concentrations, as well as incubation times, were optimized for maximum signal-to-background ratio while maintaining linear initial rate conditions at a fixed substrate concentration below Km.

[0169] Fluorescence signals were measured with an EnVision Plate Reader (PerkinElmer) equipped with a 485 nm excitation filter and a 535 nm emission filter. Measurements were performed at 2.5 min intervals for 10 min and the curves were shown to be linear.

[0170] The rate was calculated by the formula: Rate = ((Final FLU - Initial FLU) / 600 seconds), where final FLU = fluorescence emission at 10 minutes, initial FLU = fluorescence emission at 0 minutes, and 600 = reaction time (seconds).

[0171] Data were expressed as percent inhibition compared to control wells according to the formula: %inh=100×((Rate-AveLow) / (AveHigh-AveLow)), where Rate=measured rate of fluorescence generated during the assay, AveLow=average rate for no enzyme controls (n=32), and AveHigh=average rate for DMSO controls (n=32).

[0172] I C 50 Values ​​were determined by curve fitting using the standard four-parameter logistic fitting algorithm included in the Activity Base software package (IDBS) using XE Designer Model 250. Data fitting was performed using the Levenberg-Marquardt algorithm. IC values ​​for the specific substances performed were 50 is shown in Table A.

[0173] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11]

[0174] This disclosure enables those skilled in the relevant art to implement and use the invention provided herein according to multiple and various embodiments. Various changes, substitutions, and improvements of the disclosure that can be easily thought of by those skilled in the art, including specific changes, variations, substitutions, and improvements, are included as part of this disclosure. Therefore, the above description is an example to explain the findings provided herein. Furthermore, the above description and examples are illustrative of the present invention, but not limiting. Therefore, the scope of the present invention is described in the appended claims.

Claims

1. Compound of formula (II) 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, Y is N or CH; R １ but, 1 to 3 R ２ (C １ -C ４ ) alkyl, One R ３ (C ３ -C ６ ) cycloalkyl, 1-2 R ４ aryl optionally substituted with One R ５ heteroaryl substituted with One (C １ -C ４ ) a bicyclic heteroaryl optionally substituted with alkyl; partially saturated bicyclyl optionally substituted with one halogen, and 【Chemistry 2】 is selected from Each R ２ However, each independently, (C １ -C ４ ) alkyl, (C ３ -C ６ ) cycloalkyl, (C ６ -C １２ ) spirocycloalkyl, One halogen or -OR ６ aryl, optionally substituted with selected from 3- to 6-membered heterocyclyl; R ３ But (C １ -C ４ ) alkyl; Each R ４ each independently may be optionally substituted with halogen (C １ -C ４ ) alkyl, -OR ６ , halogen, and 3- to 6-membered heterocyclyl; R ５ is aryl substituted with one halogen; R ６ is optionally substituted with aryl and halogen (C １ -C ４ ) alkyl; R １０ is hydrogen or halogen; R １１ is halogen or halogen-substituted (C １ -C ３ ) alkyl.

2. R ２ The compound of claim 1, wherein is selected from the group consisting of methyl, cyclopropyl fused to cyclohexyl, pyrrolidinyl, and phenyl optionally substituted with one -Cl.

3. R ２ The compound of claim 1 or 2, wherein is selected from the group consisting of methyl, spiro[5.2]octane, pyrrolidinyl, and phenyl optionally substituted with one -Cl.

4. R １０ The compound of claim 1, wherein is hydrogen or -Cl.

5. R １１ The compound of claim 1 or 4, wherein is -Cl or trifluoromethyl. 【Request 6】 【Chemical 3-1】 【Chemistry 3-2】 【Chemistry 3-3】 A compound selected from the group consisting of or a pharma- ceutically acceptable salt thereof.

7. Compound of formula (III) 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof, Z is N or CH; R １２ is trifluoromethyl; R １３ is aryl or halogen; compound.

8. R １３ The compound of claim 7, wherein is phenyl or -Cl.

9. 【Chemical 5】 A compound selected from the group consisting of or a pharma- ceutically acceptable salt thereof.

10. Compound of formula (IV) 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof, R １４ is aryl substituted with halogen; R １５ is aryl.

11. The compound is 【Chemistry 7】 or a pharma- ceutically acceptable salt thereof.

12. Compound of formula (V) 【Chemistry 8】 or a pharma- ceutically acceptable salt thereof, R １６ is a halogen; R １７ is substituted with halogen (C １ -C ４ ) alkyl; R １８ is an aryl substituted with a halogen.

13. The compound is 【Chemistry 9】 or a pharma- ceutically acceptable salt thereof.

14. Compound of formula (VI) 【Chemistry 10】 or a pharma- ceutically acceptable salt thereof, R １９ is a halogen; R ２０ is substituted with halogen (C １ -C ４ ) alkyl; R ２１ is an aryl substituted with a halogen.

15. The compound is 【Chemistry 11】 or a pharma- ceutically acceptable salt thereof.

Images